Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aims: Vedolizumab is indicated for the treatment of chronic pouchitis in the European Union. We assessed whether vedolizumab induced mucosal healing (MH) and if MH was associated with clinical improvements.
Methods: EARNEST, a randomized, double-blind, placebo-controlled study, evaluated vedolizumab efficacy and safety in adults with chronic pouchitis. Centrally read endoscopic and histologic evaluation was performed at baseline, Week (W)14, and W34. Ulcer count, adapted Simple Endoscopic Score for Crohn's Disease in the pouch, and Pouchitis Disease Activity Index histologic component were evaluated. Pouchitis Disease Activity Index and Inflammatory Bowel Disease Questionnaire remission at W14 and W34 were compared by MH status at W14.
Results: Following treatment, mean (standard deviation) number of ulcers in vedolizumab-treated patients reduced from 15.1 (16.4) to 5.0 (4.9) at W14 and 2.7 (3.2) at W34 versus placebo-treated patients with corresponding values of 11.8 (11.3), 13.4 (18.4), and 9.7 (13.8) (vedolizumab vs placebo difference [95% confidence interval]: W14: -8.4 [-14.3, -2.6]; W34: -7.0 [-12.0, -2.0]). More patients receiving vedolizumab versus placebo achieved reduction in ulcerated pouch surface area (W14: 52.4% vs 20.0%; difference, 32.4 percentage points [p.p] [9.7, 51.4]; W34: 52.1% vs 12.9%; difference, 40.2p.p [15.6, 60.3]), absence of ulceration (W14: 23.8% vs 7.5%; difference, 16.3p.p [1.1, 31.6]; W34: 34.4% vs 15.6%; difference, 18.8p.p [-2.0, 39.5]), Simple Endoscopic Score for Crohn's Disease remission (W14: 23.8% vs 7.5%; difference, 16.3p.p [1.1, 31.6]; W34: 34.4% vs 15.6%; difference, 18.8p.p [-2.0, 39.5]), and MH (W14: 16.7% vs 2.5%; difference, 14.2p.p [1.9, 26.4]). Patients with MH at W14 had higher rates of Pouchitis Disease Activity Index and Inflammatory Bowel Disease Questionnaire remission at W14 and W34 than those without.
Conclusions: Vedolizumab induced endoscopic improvements in patients with chronic pouchitis, which was associated with improved outcomes at W34, particularly in patients achieving MH at W14. (ClinicalTrials.gov number, NCT02790138.).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2024.06.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Outcomes of First-Line Anti-TNF Therapy for Chronic Inflammatory Pouch Conditions: A Multi-Centre Multi-National Study.
Biomedicines
August 2025
Department of Gastroenterology, St Mark's National Bowel Hospital & Academic Institute, London NW10 7NS, UK.
Anti-tumour necrosis factor (anti-TNF) medications were historically commonly prescribed as the first-line biologic treatment for chronic inflammatory pouch conditions. However, their use in these conditions is mainly based on retrospective studies of relatively small numbers of patients with short follow up periods. We aimed to describe the long-term outcomes of first-line anti-TNF therapy in a large, multi-centre, multi-national patient cohort with chronic inflammatory pouch conditions.
View Article and Find Full Text PDFIncidence and Long-Term Outcomes of Pouchitis in Ulcerative Colitis Patients.
United European Gastroenterol J
August 2025
Gastro Unit, Medical Section, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark.
Background: Ileal pouch-anal anastomosis (IPAA) is the preferred intervention for ulcerative colitis (UC) patients whose medical treatment fails. Acute severe ulcerative colitis (ASUC) can precipitate the need for urgent surgery, potentially influencing post-IPAA outcomes.
Objective: This study details the incidence, disease course, and treatment of pouchitis and pouch failure in a population-based cohort of UC patients following IPAA construction.
Development and External Validation of an Endoscopic and Histologic Pouchitis Assessment Tool: The Atlantic Pouchitis Index.
Clin Gastroenterol Hepatol
July 2025
Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Alimentiv Inc, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. Electronic address:
Background & Aims: No fully validated indices to measure pouchitis activity exist. We aimed to develop and externally validate a novel endoscopic and histologic index.
Methods: Endoscopists and pathologists used 11 (4 endoscopic, 4 histologic, 3 composite) existing indices and items from a prior Research and Development/University of California Los Angeles appropriateness exercise to assess pouchitis disease activity in videos and images from 98 patients with chronic antibiotic-refractory pouchitis who participated in a randomized placebo-controlled alicaforsen trial.
Pouchitis is the most common complication following ileal pouch-anal anastomosis. It is characterized by pouch inflammation and symptoms resembling ulcerative colitis. The aetiology is thought to involve a combination of genetic factors, a dysregulated immune response, and alterations in the gut microbiome.
View Article and Find Full Text PDFA Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch.
Am J Gastroenterol
June 2025
Division of Gastroenterology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Introduction: Many patients with chronic pouchitis and Crohn's-like disease of the pouch (CLDP) are treated with biologics; however, the comparative effectiveness of advanced therapies in this population has not been systematically evaluated. We sought to compare the effectiveness of antitumor necrosis factor α (anti-TNF) therapies and ustekinumab in patients with chronic inflammatory conditions of the pouch.
Methods: We conducted a prospective, multicenter, cohort study.